Observational analysis shows tirzepatide improves clinical outcomes in type 2 diabetes and obesity, suggesting enhanced efficacy over semaglutide and insulin.
Introduction: The increasing prevalence of type 2 diabetes and obesity highlights the need for therapies that address both glycemic control and weight reduction. Tirzepatide, a dual GIP and GLP-1 receptor agonist, has shown superior results compared to semaglutide and insulin glargine. Imaging techniques provide objective evidence of its structural and functional benefits.
No takes yet. Share an insight, caveat, or question.
Barros et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: